The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10054 malaria professionals are enjoying the free benefits of MalariaWorld today

falciparum

NOT Open Access | Baseline Ex Vivo and Molecular Responses of Plasmodium falciparum Isolates to Piperaquine before Implementation of Dihydroartemisinin-Piperaquine in Senegal

April 30, 2019 - 15:21 -- NOT Open Access
Author(s): 
Marie Gladys Robert, Francis Foguim Tsombeng, Mathieu Gendrot, Silman Diawara, Marylin Madamet, Mame Bou Kounta, Khalifa Ababacar Wade, Mansour Fall, Mamadou Wague Gueye, Nicolas Benoit, Aminata Nakoulima, Raymond Bercion, Rémy Amalvict, Bécaye Fall, Boubacar Wade, Bakary Diatta and Bruno Pradines
Reference: 
Antimicrob. Agents Chemother. April 2019 63:e02445-18

Dihydroartemisinin-piperaquine, which was registered in 2017 in Senegal, is not currently used as the first-line treatment against uncomplicated malaria. A total of 6.6% to 17.1% of P. falciparum isolates collected in Dakar in 2013 to 2015 showed ex vivo-reduced susceptibility to piperaquine. 

Country: 
Medical Treatment: 

NOT Open Access | Mutation Profile of pfdhfr and pfdhps in Plasmodium falciparum among Returned Chinese Migrant Workers from Africa

April 30, 2019 - 15:18 -- NOT Open Access
Author(s): 
Chao Xu, Hui Sun, Qingkuan Wei, Jin Li, Ting Xiao, Xiangli Kong, Yongbin Wang, Guihua Zhao, Longjiang Wang, Gongzhen Liu, Ge Yan, Bingcheng Huang and Kun Yin
Reference: 
Antimicrob. Agents Chemother. April 2019 63:e01927-18

We evaluated markers of sulfadoxine-pyrimethamine (SP) resistance in Plasmodium falciparum among 254 returned migrant workers in China from Africa from 2013 to 2016.

Continent: 
Medical Condition: 

NOT Open Access | Identification of Antimalarial Compounds That Require CLAG3 for Their Uptake by Plasmodium falciparum-Infected Erythrocytes

April 30, 2019 - 15:17 -- NOT Open Access
Author(s): 
Sofía Mira-Martínez, Anastasia K. Pickford, Núria Rovira-Graells, Pieter Guetens, Elisabet Tintó-Font, Alfred Cortés and Anna Rosanas-Urgell
Reference: 
Antimicrob. Agents Chemother. April 2019 63:e00052-19

During the intraerythrocytic asexual cycle malaria parasites acquire nutrients and other solutes through a broad selectivity channel localized at the membrane of the infected erythrocyte termed the plasmodial surface anion channel (PSAC). The protein product of the Plasmodium falciparum clonally variant clag3.1 and clag3.2 genes determines PSAC activity. Switches in the expression of clag3 genes, which are regulated by epigenetic mechanisms, are associated with changes in PSAC-dependent permeability that can result in resistance to compounds toxic for the parasite, such as blasticidin S. Here, we investigated whether other antimalarial drugs require CLAG3 to reach their intracellular target and consequently are prone to parasite resistance by epigenetic mechanisms. 

Medical Condition: 

Antibodies to Peptides in Semiconserved Domains of RIFINs and STEVORs Correlate with Malaria Exposure

April 30, 2019 - 15:03 -- Open Access
Author(s): 
Albert E. Zhou, Andrea A. Berry, Mark A. Travassos, et al.
Reference: 
mSphere March/April 2019 4:e00097-19

The repetitive interspersed family (RIFIN) and the subtelomeric variable open reading frame (STEVOR) family represent two of three major Plasmodium falciparum variant surface antigen families involved in malaria pathogenesis and immune evasion and are potential targets in the development of natural immunity. Protein and peptide microarrays populated with RIFINs and STEVORs associated with severe malaria vulnerability in Malian children were probed with adult and pediatric sera to identify epitopes that reflect malaria exposure.

Medical Condition: 

Cell-traversal protein for ookinetes and sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies that inhibit Plasmodium falciparum infection in Anopheles stephensi

April 29, 2019 - 13:13 -- Open Access
Author(s): 
Sakineh Pirahmadi, Sedigheh Zakeri, Akram A. Mehrizi, Navid D. Djadid, Abbas-Ali Raz, Jafar J. Sani, Ronak Abbasi and Zahra Ghorbanzadeh
Reference: 
Malaria Journal 2019 18:146, 24 April 2019

Plasmodium falciparum parasite is the most deadly species of human malaria, and the development of an effective vaccine that prevents P. falciparum infection and transmission is a key target for malarial elimination and eradication programmes. P. falciparum cell-traversal protein for ookinetes and sporozoites (PfCelTOS) is an advanced vaccine candidate. A comparative study was performed to characterize the immune responses in BALB/c mouse immunized with Escherichia coli-expressed recombinant PfCelTOS (rPfCelTOS) in toll-like receptor (TLR)-based adjuvants, CpG and Poly I:C alone or in combination (CpG + Poly I:C), followed by the assessment of transmission-reducing activity (TRA) of anti-rPfCelTOS antibodies obtained from different vaccine groups in Anopheles stephensi.

Medical Condition: 

A novel approach to identifying patterns of human invasion-inhibitory antibodies guides the design of malaria vaccines incorporating polymorphic antigens

August 15, 2017 - 16:30 -- Open Access
Author(s): 
Drew D, Wilson D, Elliott S, Cross N, Terheggen U, Hodder A, Siba P, Chelimo K, Dent A, Kazura J, Mueller I, Beeson J
Reference: 
BMC Medicine 2016, 14 :144 (23 September 2016)

We found that AMA1 was a major target of naturally acquired invasion-inhibitory antibodies that were highly prevalent in malaria-endemic populations and showed a high degree of allele specificity. Significantly, the prevalence of inhibitory antibodies to different alleles varied substantially within populations and between geographic locations.

An optimised age-based dosing regimen for single low-dose primaquine for blocking malaria transmission in Cambodia

August 15, 2017 - 16:18 -- Open Access
Author(s): 
Leang R, Khu N, Mukaka M, Debackere M, Tripura R, Kheang S, Chy S, Kak N, Buchy P, Tarantola A, Menard D, Roca-Felterer A, Fairhurst R, Kheng S, Muth S, Ngak S, Dondorp A, White N, Taylor W
Reference: 
BMC Medicine 2016, 14 :171 (27 October 2016)

In 2012, the World Health Organization recommended the addition of single low-dose primaquine (SLDPQ, 0.25 mg base/kg body weight) to artemisinin combination therapies to block the transmission of Plasmodium falciparum without testing for glucose-6-phosphate dehydrogenase deficiency. 

Clinical and molecular surveillance of artemisinin resistant falciparum malaria in Myanmar (2009–2013)

August 15, 2017 - 14:40 -- Open Access
Author(s): 
Myat Htut Nyunt, Myat Thu Soe, Hla Win Myint, Htet Wai Oo, Moe Moe Aye, Soe Soe Han, Ni Ni Zaw, Cho Cho, Phyo Zaw Aung, Khin Thiri Kyaw, Thin Thin Aye, Naychi Aung San, Leonard Ortega, Krongthong Thimasarn, Maria Dorina G. Bustos, Sherwin Galit…
Reference: 
Malaria Journal 2017 16:333, 14 August 2017

Apart from k13, pfarps10, pffd and pfmdr2 are also useful for molecular surveillance of artemisinin resistance especially where k13 mutation has not been reported.

Life-span of in vitro differentiated Plasmodium falciparum gametocytes

August 15, 2017 - 14:37 -- Open Access
Author(s): 
Tamirat Gebru, Albert Lalremruata, Peter G. Kremsner, Benjamin Mordmüller and Jana Held
Reference: 
Malaria Journal 2017 16:330, 11 August 2017

Plasmodium falciparum mature gametocytes can survive up to 16–32 days (at least 14 days for mature male gametocytes) in vitro in absence of the influence of host factors.

NOT Open Access | An in silico strategy for identification of novel drug targets against Plasmodium falciparum

August 14, 2017 - 15:58 -- NOT Open Access
Author(s): 
Subhashree Rout, Namrata Priyadarshini Patra & Rajani Kanta Mahapatra
Reference: 
Parasitology Research, September 2017, Volume 116, Issue 9, pp 2539–2559

The apicomplexan parasite Plasmodium falciparum is responsible for global malaria burden. With the reported resistance to artemisinin chemotherapy, there is an urgent need to maintain early phase drug discovery and identify novel drug targets for successful eradication of the pathogen from the host.

Pages

Subscribe to RSS - falciparum